247 related articles for article (PubMed ID: 27251417)
1. Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions.
Paulzen M; Haen E; Gründer G; Lammertz SE; Stegmann B; Schruers KR; Walther S; Schoretsanitis G
J Psychopharmacol; 2016 Aug; 30(8):803-9. PubMed ID: 27251417
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy.
Paulzen M; Haen E; Hiemke C; Stegmann B; Lammertz SE; Gründer G; Schoretsanitis G
Br J Clin Pharmacol; 2017 Aug; 83(8):1668-1675. PubMed ID: 28160505
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic Drug-Drug Interactions of Mood Stabilizers and Risperidone in Patients Under Combined Treatment.
Schoretsanitis G; Haen E; Gründer G; Stegmann B; Schruers KR; Hiemke C; Lammertz SE; Paulzen M
J Clin Psychopharmacol; 2016 Dec; 36(6):554-561. PubMed ID: 27811552
[TBL] [Abstract][Full Text] [Related]
4. Effect of smoking on risperidone pharmacokinetics - A multifactorial approach to better predict the influence on drug metabolism.
Schoretsanitis G; Haen E; Stegmann B; Hiemke C; Gründer G; Paulzen M
Schizophr Res; 2017 Jul; 185():51-57. PubMed ID: 27993531
[TBL] [Abstract][Full Text] [Related]
5. Clinical response in a risperidone-medicated naturalistic sample: patients' characteristics and dose-dependent pharmacokinetic patterns.
Paulzen M; Haen E; Stegmann B; Unterecker S; Hiemke C; Gründer G; Schoretsanitis G
Eur Arch Psychiatry Clin Neurosci; 2017 Jun; 267(4):325-333. PubMed ID: 27695935
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics.
Paulzen M; Schoretsanitis G; Stegmann B; Hiemke C; Gründer G; Schruers KRJ; Walther S; Lammertz SE; Haen E
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Jun; 76():101-106. PubMed ID: 28302501
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of risperidone in different application forms - Comparing long-acting injectable and oral formulations.
Schoretsanitis G; de Leon J; Haen E; Stegmann B; Hiemke C; Gründer G; Paulzen M
Eur Neuropsychopharmacol; 2018 Jan; 28(1):130-137. PubMed ID: 29153926
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic patterns of risperidone-associated adverse drug reactions.
Schoretsanitis G; Stegmann B; Hiemke C; Gründer G; Schruers KR; Walther S; Lammertz SE; Haen E; Paulzen M
Eur J Clin Pharmacol; 2016 Sep; 72(9):1091-8. PubMed ID: 27376639
[TBL] [Abstract][Full Text] [Related]
9. Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesis.
Paulzen M; Haen E; Stegmann B; Hiemke C; Gründer G; Lammertz SE; Schoretsanitis G
Psychoneuroendocrinology; 2016 Nov; 73():9-15. PubMed ID: 27448523
[TBL] [Abstract][Full Text] [Related]
10. Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes.
Kneller LA; Abad-Santos F; Hempel G
Clin Pharmacokinet; 2020 Jan; 59(1):51-65. PubMed ID: 31359271
[TBL] [Abstract][Full Text] [Related]
11. Risperidone-induced extrapyramidal side effects: is the need for anticholinergics the consequence of high plasma concentrations?
Schoretsanitis G; Haen E; Hiemke C; Gründer G; Stegmann B; Schruers KR; Veselinovic T; Lammertz SE; Paulzen M
Int Clin Psychopharmacol; 2016 Sep; 31(5):259-64. PubMed ID: 27167902
[TBL] [Abstract][Full Text] [Related]
12. Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known CYP2D6 Genotype.
Molden E; Waade RB; Hoff M; Haslemo T
Basic Clin Pharmacol Toxicol; 2016 Nov; 119(5):470-475. PubMed ID: 27145399
[TBL] [Abstract][Full Text] [Related]
13. Effect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patients.
Suzuki Y; Fukui N; Tsuneyama N; Watanabe J; Ono S; Sugai T; Saito M; Inoue Y; Someya T
Hum Psychopharmacol; 2012 Jan; 27(1):43-6. PubMed ID: 22745940
[TBL] [Abstract][Full Text] [Related]
14. Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients.
Kang RH; Jung SM; Kim KA; Lee DK; Cho HK; Jung BJ; Kim YK; Kim SH; Han C; Lee MS; Park JY
J Clin Psychopharmacol; 2009 Jun; 29(3):272-7. PubMed ID: 19440082
[TBL] [Abstract][Full Text] [Related]
15. Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.
Vandenberghe F; Guidi M; Choong E; von Gunten A; Conus P; Csajka C; Eap CB
Clin Pharmacokinet; 2015 Dec; 54(12):1259-72. PubMed ID: 26129906
[TBL] [Abstract][Full Text] [Related]
16. Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study.
Uchida H; Mamo DC; Pollock BG; Suzuki T; Tsunoda K; Watanabe K; Mimura M; Bies RR
Ther Drug Monit; 2012 Apr; 34(2):182-7. PubMed ID: 22377743
[TBL] [Abstract][Full Text] [Related]
17. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.
Jukic MM; Smith RL; Haslemo T; Molden E; Ingelman-Sundberg M
Lancet Psychiatry; 2019 May; 6(5):418-426. PubMed ID: 31000417
[TBL] [Abstract][Full Text] [Related]
18. Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach.
Kneller LA; Hempel G
Pharm Res; 2020 May; 37(6):110. PubMed ID: 32476097
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects.
Choong E; Polari A; Kamdem RH; Gervasoni N; Spisla C; Jaquenoud Sirot E; Bickel GG; Bondolfi G; Conus P; Eap CB
J Clin Psychopharmacol; 2013 Jun; 33(3):289-98. PubMed ID: 23609392
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder.
Vermeulen A; Piotrovsky V; Ludwig EA
J Pharmacokinet Pharmacodyn; 2007 Apr; 34(2):183-206. PubMed ID: 17136449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
